GALNT2 and central nervous system cancer: Compared with low-grade glioma patients (WHO grade II and grade III), GBM patients (WHO IV) group exhibited the highest GALNT2 mRNA expression, and GALNT2 mRNA expression level was highly related to patients’ grades (Figure 1A).